Aktuelle Neurologie 2011; 38(05): 222-233
DOI: 10.1055/s-0031-1284409
Neues in der Neurologie
Georg Thieme Verlag KG Stuttgart · New York

Neues zu neurologischen Bewegungsstörungen 2011

What’s New in Movement Disorders 2011
C. Oberschmidt
1   Klinik für Neurologie, Goethe-Universität, Frankfurt am Main
,
R. Hilker
1   Klinik für Neurologie, Goethe-Universität, Frankfurt am Main
,
J. S. Kang
1   Klinik für Neurologie, Goethe-Universität, Frankfurt am Main
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. August 2011 (online)

Zusammenfassung

Das Gebiet der neurologischen Bewegungsstörungen befindet sich in einer besonders dynamischen Entwicklung. Dieser Artikel fasst neue und aus Sicht der Autoren wichtige Erkenntnisse zu nosologischen, pathophysiologischen, diagnostischen und therapeutischen Aspekten von Erkrankungen des extrapyramidal-motorischen Systems zusammen. Schwerpunkte liegen dabei auf den atypischen Parkinson-Syndromen, der Chorea Huntington, den hereditären Ataxien sowie auf der heterogenen Gruppe der Dystonien. Die (semi-)invasive Behandlung dieser und anderer Erkrankungen mittels Botulinumtoxin sowie mit Tiefer Hirnstimulation wird in 2 eigenen Kapiteln besonders ausführlich behandelt. Das Ziel dieser Übersicht ist die Einordnung der neuen Erkenntnisse in den Kontext bestehender Behandlungsstandards zur adäquaten klinischen Versorgung von Patienten mit neurologischen Bewegungsstörungen.

Abstract

Movement disorders are a dynamic and growing field in clinical neurology. This review summarises new and relevant research findings with respect to nosology, pathophysiology, diagnostics and therapy for various disorders of the extrapyramidal motor system. Main topics are atypical Parkinsonism, Huntington’s disease, hereditary ataxia and the heterogeneous group of dystonias. Particular emphasis is placed on the (semi-)invasive treatment with botulinum toxin and deep brain stimulation. The main aim of this paper is to integrate important new research findings of the last several years into the context of current management guidelines for the adequate treatment of patients with movement disorders.

 
  • Literatur

  • 1 Stefanova N, Bucke P, Duerr S et al. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178
  • 2 Schrag A, Wenning GK, Quinn N et al. Survival in multiple system atrophy. Mov Disord 2008; 23: 294-296
  • 3 Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676
  • 4 Kollensperger M, Geser F, Ndayisaba JP et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25: 2604-2612
  • 5 Watanabe H, Saito Y, Terao S et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125: 1070-1083
  • 6 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279
  • 7 Donker Kaat L, Boon AJ, Kamphorst W et al. Frontal presentation in progressive supranuclear palsy. Neurology 2007; 69: 723-729
  • 8 Williams DR, de Silva R, Paviour DC et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-1258
  • 9 Compta Y, Valldeoriola F, Tolosa E et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord 2007; 22: 1954-1958
  • 10 Williams DR, Holton JL, Strand K et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235-2241
  • 11 Respondek G, Decker S, Steinmeyer L et al. Differenzialdiagnosen der Parkinson-Krankheit: aktuelle Konsensuskriterien und Ausblicke. Fortschr Neurol Psych 2010; 78 (Suppl. 01) S8-S15
  • 12 Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI. Nervenarzt 2010; 81: 1168-1179
  • 13 Hussl A, Mahlknecht P, Scherfler C et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord 2010; 25: 2444-2449
  • 14 Morelli M, Arabia G, Salsone M et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011; 26: 527-533
  • 15 Longoni G, Agosta F, Kostic VS et al. MRI measurements of brainstem structures in patients with Richardson’s syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson’s disease. Mov Disord 2011; 26: 247-255
  • 16 Bensimon G, Ludolph A, Agid Y et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132: 156-171
  • 17 Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat med 2000; 6: 797-801
  • 18 Dodel R, Spottke A, Gerhard A et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25: 97-107
  • 19 Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008; 210: 421-427
  • 20 Bloch F, Houeto JL, Tezenas du Montcel S et al. Parkinson’s disease with camptocormia. J Neurol Neurosur Psych 2006; 77: 1223-1228
  • 21 Margraf NG, Wrede A, Rohr A et al. Camptocormia in idiopathic Parkinson’s disease: a focal myopathy of the paravertebral muscles. Mov Disord 2010; 25: 542-551
  • 22 Spuler S, Krug H, Klein C et al. Myopathy causing camptocormia in idiopathic Parkinson’s disease: a multidisciplinary approach. Mov Disord 2010; 25: 552-559
  • 23 Deuschl G, Margraf N, Spuler S et al. Camptocormia and myopathy. Mov Disord 2010; 25: 2689-2690
  • 24 Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord 2010; 25: 527-528
  • 25 de Seze MP, Creuze A, de Seze M et al. An orthosis and physiotherapy programme for camptocormia: a prospective case study. J Rehabil Med 2008; 40: 761-765
  • 26 Gerton BK, Theeler B, Samii A. Backpack treatment for camptocormia. Mov Disord 2010; 25: 247-248
  • 27 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord 2009; 24: 2027-2028
  • 28 Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009; 54: 614-623
  • 29 Fukaya C, Otaka T, Obuchi T et al. Pallidal high-frequency deep brain stimulation for camptocormia: an experience of three cases. Acta neurochirurgica 2006; 99: 25-28
  • 30 Hellmann MA, Djaldetti R, Israel Z et al. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson’s disease. Mov Disord 2006; 21: 2008-2010
  • 31 Micheli F, Cersosimo MG, Piedimonte F. Camptocormia in a patient with Parkinson disease: beneficial effects of pallidal deep brain stimulation. Case report. J Neurosurg 2005; 103: 1081-1083
  • 32 Allert N, Miskiewicz AA, Coenen VA. Deep brain stimulation for Parkinson’s disease and camptocormia? A case report. Fort Neurol Psych 2011; 79: 97-101
  • 33 Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005; 65: 355-359
  • 34 Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98
  • 35 Tabrizi SJ, Scahill RI, Durr A et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10: 31-42
  • 36 Aylward EH, Nopoulos PC, Ross CA et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011; 82: 405-410
  • 37 Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66: 366-372
  • 38 Hersch SM, Rosas HD. Neuroprotection for Huntington’s disease: ready, set, slow. Neurotherapeutics 2008; 5: 226-236
  • 39 Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57: 397-404
  • 40 Hersch SM, Gevorkian S, Marder K et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 2006; 66: 250-252
  • 41 Yang L, Calingasan NY, Wille EJ et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 2009; 109: 1427-1439
  • 42 Wang JL, Yang X, Xia K et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010; 133: 3510-3518
  • 43 Bakalkin G, Watanabe H, Jezierska J et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet 2010; 87: 593-603
  • 44 Schmitz-Hubsch T, Coudert M, Tezenas du Montcel S et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011; 26: 870-876
  • 45 Klinke I, Minnerop M, Schmitz-Hubsch T et al. Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. Cerebellum 2010; 9: 433-442
  • 46 Schmitz-Hubsch T, du Montcel ST, Baliko L et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006; 66: 1717-1720
  • 47 Trouillas P, Takayanagi T, Hallett M et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997; 145: 205-211
  • 48 Weyer A, Abele M, Schmitz-Hubsch T et al. Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord 2007; 22: 1633-1637
  • 49 Burk K, Malzig U, Wolf S et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009; 24: 1779-1784
  • 50 Schmitz-Hubsch T, Giunti P, Stephenson DA et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 2008; 71: 486-492
  • 51 Schmitz-Hubsch T, Fimmers R, Rakowicz M et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010; 74: 678-684
  • 52 Chan E, Charles P, Ribai P et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord 2011; 26: 534-538
  • 53 Ristori G, Romano S, Visconti A et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010; 74: 839-845
  • 54 Velazquez-Perez L, Rodriguez-Chanfrau J, Garcia-Rodriguez JC et al. Oral Zinc Sulphate Supplementation for Six Months in SCA2 Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurochem res 2011; DOI: 10.1007/s11064-011-0496-0.
  • 55 Ilg W, Brotz D, Burkard S et al. Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord 2010; 25: 2239-2246
  • 56 Artuch R, Aracil A, Mas A et al. Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002; 33: 190-193
  • 57 Di Prospero NA, Baker A, Jeffries N et al. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-886
  • 58 Lynch DR, Farmer JM, Tsou AY et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 2006; 66: 1711-1716
  • 59 Mariotti C, Solari A, Torta D et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679
  • 60 Kearney M, Orrell RW, Fahey M et al. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane db syst rev (Online) 2009; CD007791
  • 61 Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 2009; 256 (Suppl. 01) 25-30
  • 62 Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010; 67: 941-947
  • 63 Boddaert N, Le Quan Sang KH, Rotig A et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110: 401-408
  • 64 Velasco-Sanchez D, Aracil A, Montero R et al. Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum 2011; 10: 1-8
  • 65 Hart PE, Lodi R, Rajagopalan B et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62: 621-626
  • 66 Boesch S, Sturm B, Hering S et al. Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007; 62: 521-524
  • 67 Boesch S, Sturm B, Hering S et al. Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord 2008; 23: 1940-1944
  • 68 Buoni S, Zannolli R, Sorrentino L et al. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol 2006; 63: 1479-1482
  • 69 Broccoletti T, Del Giudice E, Amorosi S et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol 2008; 15: 223-228
  • 70 Broccoletti T, Del Giudice E, Cirillo E et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol 2011; 18: 564-570
  • 71 Djarmati A, Schneider SA, Lohmann K et al. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009; 8: 447-452
  • 72 Bressman SB, Raymond D, Fuchs T et al. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009; 8: 441-446
  • 73 Fuchs T, Gavarini S, Saunders-Pullman R et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009; 41: 286-288
  • 74 Camargos S, Scholz S, Simon-Sanchez J et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008; 7: 207-215
  • 75 Schmidt A, Jabusch HC, Altenmuller E et al. Etiology of musician’s dystonia: familial or environmental?. Neurology 2009; 72: 1248-1254
  • 76 Kang JS, Terranova C, Hilker R et al. Deficient Homeostatic Regulation of Practice-Dependent Plasticity in Writer’s Cramp. Cereb Cortex 2011; 21: 1203-1212
  • 77 Zoons E, Booij J, Nederveen AJ et al. Structural, functional and molecular imaging of the brain in primary focal dystonia – A review. NeuroImage 2011; 56: 1011-1020
  • 78 Reichel G. Emergency checklist: torticollis. MMW Fortsch Medizin 2010; 152: 40
  • 79 Reichel G, Stenner A, Jahn A. The phenomenology of cervical dystonia. Fort Neurol Psych 2009; 77: 272-277
  • 80 Paus S, Gross J, Moll-Muller M et al. Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study. J Neurol 2011; DOI: 10.1007/s00415-011-6029-6.
  • 81 Fabbrini G, Berardelli I, Moretti G et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 2010; 25: 459-465
  • 82 Kuyper DJ, Parra V, Aerts S et al. Nonmotor manifestations of dystonia: A systematic review. Mov Disord 2011; DOI: 10.1002/mds.23709.
  • 83 Voon V, Butler TR, Ekanayake V et al. Psychiatric symptoms associated with focal hand dystonia. Mov Disord 2010; 25: 2249-2252
  • 84 Altenmuller E, Jabusch HC. Focal dystonia in musicians: phenomenology, pathophysiology and triggering factors. Eur J Neurol 2010; 17 (Suppl. 01) 31-36
  • 85 Siebner HR, Auer C, Ceballos-Baumann A et al. Has repetitive transcranial magnetic stimulation of the primary motor hand area a therapeutic application in writer’s cramp?. Electroencephalogr Clin Neurophysiol 1999; 51: 265-275
  • 86 Siebner HR, Tormos JM, Ceballos-Baumann AO et al. Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer's cramp. Neurology 1999; 52: 529-537
  • 87 Murase N, Rothwell JC, Kaji R et al. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer’s cramp. Brain 2005; 128: 104-115
  • 88 Benninger DH, Lomarev M, Lopez G et al. Transcranial direct current stimulation for the treatment of focal hand dystonia. Mov Disord 2011; DOI: 10.1002/mds.23691.
  • 89 Kranz G, Shamim EA, Lin PT et al. Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study. Neurology 2010; 75: 1465-1471
  • 90 Comella CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-1429
  • 91 Wissel J, Auf dem Brinke M, Hecht M et al. Botulinum toxin in the treatment of adult spasticity: An interdisciplinary german 10-point consensus 2010. Nervenarzt 2011; 82: 481-495
  • 92 Lungu C, Karp BI, Alter K et al. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more. Mov Disord 2011; 26: 750-753
  • 93 Burbaud P, Ducerf C, Cugy E et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 2011; DOI: 10.1002/mds.23691.
  • 94 Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581-591
  • 95 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New Engl j med 2006; 355: 896-908
  • 96 Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. Jama 2009; 301: 63-73
  • 97 Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 2010; 25: 578-586
  • 98 Fasano A, Romito LM, Daniele A et al. Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 2010; 133: 2664-2676
  • 99 Espay AJ, Vaughan JE, Marras C et al. Early versus delayed bilateral subthalamic deep brain stimulation for parkinson’s disease: a decision analysis. Mov Disord 2010; 25: 1456-1463
  • 100 Fasano A, Daniele A, Albanese A. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson’s disease: Need for long-term clinical trials. Mov Disord. 2011 DOI: 10.1002/mds.23633
  • 101 Hilker R, Benecke R, Deuschl G et al. Deep brain stimulation for Parkinson’s disease. Consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt 2009; 80: 646-655
  • 102 Bronstein JM, Tagliati M, Alterman RL et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011; 68: 165
  • 103 Follett KA, Weaver FM, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New Engl j med 2010; 362: 2077-2091
  • 104 Weaver F, Follett K, Hur K et al. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005; 103: 956-967
  • 105 Antonini A, Isaias IU, Rodolfi G et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011; 258: 579-585
  • 106 Merola A, Zibetti M, Angrisano S et al. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease. Mov Disord 2011; 26: 664-670
  • 107 Tripoliti E, Zrinzo L, Martinez-Torres I et al. Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology 2011; 76: 80-86
  • 108 St George RJ, Nutt JG, Burchiel KJ et al. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010; 75: 1292-1299
  • 109 Hamani C, Moro E, Lozano AM. The pedunculopontine nucleus as a target for deep brain stimulation. J Neural Transm 2010; DOI: 10.1007/s00702-010-0547-8.
  • 110 Stefani A, Lozano AM, Peppe A et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 2007; 130: 1596-1607
  • 111 Moro E, Hamani C, Poon YY et al. Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain 2010; 133: 215-224
  • 112 Ferraye MU, Debu B, Fraix V et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 2010; 133: 205-214
  • 113 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605-614
  • 114 Daniels C, Krack P, Volkmann J et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2010; 25: 1583-1589
  • 115 Greenhouse I, Gould S, Houser M et al. Stimulation at dorsal and ventral electrode contacts targeted at the subthalamic nucleus has different effects on motor and emotion functions in Parkinson’s disease. Neuropsychologia 2010; 49: 528-534
  • 116 Torres CV, Moro E, Lopez-Rios AL et al. Deep brain stimulation of the ventral intermediate nucleus of the thalamus for tremor in patients with multiple sclerosis. Neurosurgery 2010; 67: 646-651
  • 117 Barbe MT, Liebhart L, Runge M et al. Deep brain stimulation in the nucleus ventralis intermedius in patients with essential tremor: habituation of tremor suppression. J Neurol 2010; 258: 434-439
  • 118 Hwynn N, Hass CJ, Zeilman P et al. Steady or not following thalamic deep brain stimulation for essential tremor. J Neurol 2011; DOI: 10.1007/s00415-011-5986-0.
  • 119 Plaha P, Javed S, Agombar D et al. Bilateral caudal zona incerta nucleus stimulation for essential tremor: outcome and quality of life. J Neurol Neurosurg Psychiatry 2011; DOI: 10.1136/jnnp.2010.222992.
  • 120 Schrader C, Benecke R, Deuschl G et al. Deep brain stimulation for dystonia. Consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt 2009; 80: 656-661
  • 121 Andrews C, Aviles-Olmos I, Hariz M et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1383-1389
  • 122 Azoulay-Zyss J, Roze E, Welter ML et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to epsilon-sarcoglycan mutations: a pilot study. Arch Neurol 2011; 68: 94-98
  • 123 Isaias IU, Volkmann J, Kupsch A et al. Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration. J Neurol 2011; DOI: 10.1007/s00415-011-5961-9.
  • 124 Ostrem JL, Racine CA, Glass GA et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011; 76: 870-878
  • 125 Reese R, Gruber D, Schoenecker T et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord 2011; 26: 691-698
  • 126 Ackermans L, Duits A, van der Linden C et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 2011; 134: 832-844
  • 127 Welter ML, Grabli D, Vidailhet M. Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Current Opin Neurol 2010; 23: 420-425
  • 128 Kang GA, Heath S, Rothlind J et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatry 2011; 82: 272-277
  • 129 Timmermann L, Pauls KA, Wieland K et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133: 701-712